Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by GameChangerBet on May 20, 2021 3:41pm

Markets

The general markets are currently experiencing a rotation is assets.
High risk, tech, health care, growth stocks are selling off. That money is flowing into value, high yields, and gold, and predominatly junior gold stocks. This rotation is well under way, but still in the early stages. This is why you are seeing stocks like Tesla, bitcoin, selling off.

ATE can certainly experience downward momentum in the short term as this rotation continues, certain price points are not impossible.
However, in ATE's case specifically, due to the number of expected positive developments, both in the near term and further out, it should be able to maintain a certain bottom price level until such developments are brought to market.
Comment by Forestview on May 20, 2021 3:50pm
GCB - I've enjoyed your posts.  Well written, well thought through.  You clearly are an experienced investor.  I am curious though of what you think about Dan as a leader/CEO.  As you can see on this board, many of the posts indicate a frustration in his management and leadership style (some may even say we lack confidence in his duty to keep shareholders best interest in ...more  
Comment by Actuarial on May 20, 2021 4:43pm
The only part I don't like DL is his selling his shares after PH2B. The latest bought deal is fine as the price is not too bad and the sufficent fund leave us some time room for negotiation.
Comment by GameChangerBet on May 20, 2021 4:47pm
My thoughts are as follows. John Wallace was the founder of the science, he is exceptional in his field and well recongnized by his peers in the scientific and medical community. He is not an individual with any particularly strong business acumen as far as I'm aware of. Dan Legaut happens to be his college friend who has experience in the business world. A partnership is formed. You can ...more  
Comment by MrMugsy on May 20, 2021 5:42pm
Well said GameChanger.  Nothing to argue there. What Dan has to battle every day of his ATE life is the fact that until recently, we've been cash poor.  Without money, you can't move very quickly.  If you're not moving very quickly, you're certainly not moving opportunities in parallel. So ... if you want to argue "against" Dan, you're either ...more  
Comment by GameChangerBet on May 20, 2021 10:13pm
Just to touch on a few points. I don't think Antibe being aquired at the current stage is a likely event. The further out in time you go, an aquiring event becomes more likely, given the nature of how much further along they will presumably be. This has essentially been said by management. Their strategy has been explicitly discussed. They are looking for a partner for all major markets ...more  
Comment by markymark11 on May 21, 2021 1:59am
Sigh... I wish I hadn't looked into Cassava Sciences, because now I'm very jealous of what they were able to achieve compared to Antibe. Cassava was able to get their valuation to over $1 billion on interim phase 2 data (not even the final results yet..). Antibe needs to step up their game..
Comment by Doccole on May 21, 2021 5:51am
That's on leadership and execution.  At least we have the science.   hope a deal bounces higher than agen! 
Comment by MrMugsy on May 21, 2021 7:46am
Hahaha - right Marymark. Look at it another way ... we have the potential to do much better than SAVA. ---------- I can only assume their patent life is much greater than the 5 years remaining for OTENA. Also keep in mind that it doesn't get any better with 352 and 340 ... if they get to market. But ... The value is in the patents and what we can do with them. So ... we need a big OTENA ...more  
Comment by StockingUp21 on May 21, 2021 7:49am
No effort made to make us like them before multiple dilution hurts the future.   
Comment by MrMugsy on May 21, 2021 8:09am
I don't think it's about a lack of effort ... and ... I seriously doubt that the dilutions are going to hurt our future (need to wait for the verdict on that one). Fact is ... if you don't have cash in this business ... you can't do anything.  You need money to move drugs forward.  No one can dispute that - and cash is something we never really had. We're a small ...more  
Comment by Doccole on May 21, 2021 8:29am
I don't think covid is going to be a issue for the study.  I was worried, but all our American hospitals are being told business as usual within 3 months.   ATE being aligned with AH is huge.  I am glad that's done.  I anticipate a LATAM deal announced within 2 months with GUD.  
Comment by MrMugsy on May 21, 2021 8:39am
I agree Doccole.  I asked Dan about risk assessment and our strategy re. COVID ... there seems to be enough in the plans to get us started at sites where COVID is less likely to be a concern - and - we can start in multiple countries (hand-picking sites), further limiting the effects of COVID. I too thought a LATAM deal would come first - but - word on the street is that ATE is focused on ...more  
Comment by Doccole on May 21, 2021 9:37am
From your talks with Dan- do you think a chance of buyout has increased ? Or are we still looking at partnership?
Comment by MrMugsy on May 21, 2021 9:57am
Not from my talks with Dan but I would only guess that Big Pharma isn't prepared to spend the kind of money that we are looking to receive.  We have to prove ourselves first. My guess is that we're looking at large partnerships for OTENA  - but - I'm sure things could change quickly.  All depends where the talks go - if they see eye-to-eye or if the data convinces a Big ...more  
Comment by Actuarial on May 21, 2021 10:03am
ATE has not determine lowest effective dose yet. I see this be a key for BP to consider parnership deal or buy out. 
Comment by MrMugsy on May 21, 2021 11:05am
Yes - absolutely ... and I hope we learn about a lower dose when we're on the NASDAQ. Would be exciting information at that time.
Comment by Actuarial on May 21, 2021 9:20am
Dilution sounds bad. In reality, you need cash. And, if you were able to attract inflow of money, it is actually great because the company has a merit in investors' eyes. The worst situation is, you believe that you have great science but you have nowhere to finance the development, alike ATE several years ago when a liar destroyed PH1. The dark time is over. We will see something real in fall ...more  
Comment by Edou111 on May 21, 2021 9:36am
"a liar destroyed PH1"  Can you explain ?  Thanks
Comment by Actuarial on May 21, 2021 9:41am
Someone who participate Ph1 lied to ATE about his existing liver disease. And later on, show severe adverse effect in high dose (1400mg?) group and was sent to hospital. ATE halt the clinical trial and lose more than 90% of market cap in single day.
Comment by WalkOverTheStrt on May 21, 2021 12:50pm
Mugs  Not tracking this "I can only assume their patent life is much greater than the 5 years remaining for OTENA"  Otenal loses US exclusivity in 2032. slide 20 https://antibethera.com/wp-content/uploads/2021/04/Antibe-Corporate-Presentation-April-2021.pdf BTW funny story on SAVA - had 3K shares / $9 avg pps and bought right after the posiitve earlier PH2 study ...more  
Comment by MrMugsy on May 21, 2021 2:49pm
Depending when we actually come to market ... if later than expected for any delay ... we will get a minimum of 5 years in USA and 7 years in Europe (or shomething like that).  That's all I meant by that comment. No drugs to date have impressed - agreed - but I'm banking on H2S making a big difference as per the studies on H2S for AD as we shared here in the past.
Comment by WalkOverTheStrt on May 21, 2021 7:25pm
Mugs  I count min of 7 years in USA per their corp presenation and assuming they do the math correctly on FDA NDA / commercilaization.  Start in full year 2025 thru to 2031, loss exclusivity in 2032.  Phase 3 completes end of 2022 early 2022 Q1/Q2 leaves 2.5 years for them to get FDA approval (their slated 2025 start). A BP could get their quicker 9results of PH3/package ...more  
Comment by markymark11 on May 21, 2021 4:02pm
Patent protection for both companies appears to be similar, based on each company's most recent corporate presentation. From Cassava Sciences: "Composition of matter patent protection for simufilam and other novel filamin-binding molecules includes six issued patents and currently runs through 2033." May 2021 Corporate Presentation, Slide 33 - https://www.cassavasciences.com ...more  
Comment by MrMugsy on May 21, 2021 5:29pm
Exellent - Thanks Markymark. That makes comparing easier. So imagine if we could develop a drug that gets to the brain cells and provides the deficient H2S where it's needed ... along with an active ingredient like an off-patent Rivastigmine. Can't wait to see how we might perform in that arena ! It all takes time but if we're lucky ... well worth the wait. : )
Comment by StockingUp21 on May 21, 2021 7:47am
Leadership means more than science in some case. There is not a leader here